(Q46119680)

English

Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis

scientific article published on 13 February 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19222510

Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis (English)

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19222510

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19222510

2

object named as

M D Ferrari

1 reference

Europe PubMed Central

19 December 2017

Peter J. Goadsby

1

object named as

P J Goadsby

1 reference

Europe PubMed Central

19 December 2017

author name string

A Csanyi

3

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19222510

J G Mills

5

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19222510

Tonabersat TON-01-05 Study Group

6

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19222510

language of work or name

0 references

publication date

13 February 2009

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19222510

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19222510

29

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19222510

742-750

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19222510

7

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19222510

The global burden of disease study: implications for neurology

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

Migraine--current understanding and treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

Cost of disorders of the brain in Europe

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

Burden of migraine in the United States: disability and economic costs.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

The pharmacology of headache

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

Migraine prevalence, disease burden, and the need for preventive therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

Epidemiology of headache in a general population--a prevalence study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

Identification of (-)-cis-6-acetyl-4S-(3-chloro-4-fluoro-benzoylamino)- 3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3S-ol as a potential antimigraine agent.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

Mechanisms of migraine aura revealed by functional MRI in human visual cortex

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

SB-220453, a potential novel antimigraine agent, inhibits nitric oxide release following induction of cortical spreading depression in the anaesthetized cat.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

Nitric oxide in primary headaches

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

Subcutaneous sumatriptan during the migraine aura

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

Cortical spreading depression produces increased cGMP levels in cortex and brain stem that is inhibited by tonabersat (SB-220453) but not sumatriptan

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

Tonabersat (SB-220453) a novel benzopyran with anticonvulsant properties attenuates trigeminal nerve-induced neurovascular reflexes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

Joint 1994 Wolff Award Presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

Pathophysiology of the migraine aura. The spreading depression theory

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

Suppression of cortical spreading depression in migraine prophylaxis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

Serotonin receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: a migraine target?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

Topiramate inhibits trigeminovascular neurons in the cat.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

Topiramate for migraine prevention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

Topiramate in migraine prevention: results of a large controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2008.01804.X

21 January 2018

Identifiers

10.1111/J.1468-2982.2008.01804.X

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19222510

1 reference

Europe PubMed Central

19 December 2017

http://europepmc.org/abstract/MED/19222510

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46119680&oldid=2093416220"